Cognitive assessment in the Accelerating Medicines Partnership® Schizophrenia Program: harmonization priorities and strategies in a diverse international sample.
Allott K, Yassin W, Alameda L, Billah T, Borders O, Buccilli K, Carrión RE, Castillo-Passi RI, Cho KIK, Chin K, Coleman MJ, Colton BL, Corral S, Dwyer D, Gundersen KB, Gur RC, Hoftman GD, Jacobs GR, Kelly S, Lewandowski KE, Marcy PJ, Matneja P, McLaughlin D, Nunez AR, Parsa S, Penzel N, Ray S, Reinen JM, Ruparel K, Sand MS, Santorelli G, Seitz-Holland J, Spark J, Tamayo Z, Thompson A, Tod S, Wannan CMJ, Wickham A, Wood SJ, Zoupou E, Addington J, Anticevic A, Arango C, Breitborde NJK, Broome MR, Cadenhead KS, Calkins ME, Chen EYH, Choi J, Conus P, Corcoran CM, Cornblatt BA, Ellman LM, Fusar-Poli P, Gaspar PA, Gerber C, Glenthøj LB, Horton LE, Hui CLM, Kambeitz J, Kambeitz-Ilankovic L, Keshavan M, Kim SW, Koutsouleris N, Kwon JS, Langbein K, Mamah D, Diaz-Caneja CM, Mathalon DH, Mittal VA, Nordentoft M, Pearlson GD, Perkins DO, Perez J, Powers AR 3rd, Rogers J, Sabb FW, Schiffman J, Shah JL, Silverstein SM, Smesny S, Strauss GP, Thompson JL, Upthegrove R, Verma SK, Wang J, Wolf DH, Pasternak O, Bouix S, McGorry PD, Kane JM, Kahn RS, Bearden CE, Shenton ME, Woods SW, Nelson B; Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ); Stone WS.
Allott K, et al.
Schizophrenia (Heidelb). 2025 Mar 24;11(1):49. doi: 10.1038/s41537-025-00578-1.
Schizophrenia (Heidelb). 2025.
PMID: 40128256
Free PMC article.